Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12617MR)

This product GTTS-WQ12617MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer, Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12617MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12116MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ13464MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ2163MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ386MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ11649MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ5385MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ10604MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ9409MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW